Atlas Trials

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Clinical trial NCT02501629 · COMPLETED

Trial details

NCT number
NCT02501629
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
AsthmaElevated Blood EosinophilsOral Corticosteroid Dependence
Start date
2015-09-29
Primary completion
2017-06-19
Enrollment
177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.